Antibody Detection + Antibody Testing of Serious Fungal Infections

In order to maintain good business practices, MiraVista Diagnostics is providing a 90-day notice of pending updates to our referral testing customers. Beginning March 1, 2021 MiraVista Diagnostics will transition to an improved MVista® Histoplasma Antigen Quantitative EIA. The new…
READ MORE →

Are You Underdiagnosing Coccidioidomycosis? Capture Additional Cases with Combined Antigen and Antibody Testing. Dear Colleagues, The prevailing method for diagnosis of coccidioidomycosis is serum antibody testing by immunodiffusion (ID) with a sensitivity of 84.2% and specificity of 96.5%, but a…
READ MORE →

In order to maintain good business practices, MiraVista Diagnostics is providing a 90-day notice of pending updates to our test report format to our referral testing customers. Minor changes have been made to the layout, while critical information such as…
READ MORE →

MiraVista is open and continues to provide critical diagnostic testing despite the impact COVID-19 has had on staffing. The health and welfare of our team is of critical importance. To limit the opportunity of exposure to COVID-19 for our entire…
READ MORE →

In compliance with the National Institutes of Health Office of Science Policy (NIH OSP), MiraVista Diagnostics LLC has formed an Institutional Biosafety Committee (IBC) to review, approve and confirm that the company’s research involving recombinant/synthetic DNA complies with NIH guidelines….
READ MORE →

Early and accurate diagnosis of coccidioidomycosis, also known as Valley fever, is critical for appropriate disease treatment and management. Current serodiagnosis is based on the detection of patient serum antibodies that react with tube precipitin (TP) and complement fixation (CF)…
READ MORE →